Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04958031
Study type Interventional
Source Cerevel Therapeutics, LLC
Contact Cerevel Clinical Trial Support
Email cerevelclinicaltrials@cerevel.com
Status Recruiting
Phase Phase 2
Start date June 22, 2021
Completion date October 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05389644 - TMS as a Treatment for Apathy in Alzheimer's Disease N/A
Recruiting NCT06047522 - Benefit of Virtual Reality Headset Use on Apathy in Older Adults With Major Neurocognitive Disorders N/A
Completed NCT01047254 - Bupropion for the Treatment of Apathy in Alzheimer's Dementia Phase 3
Recruiting NCT05561205 - rTMS for Apathy Clinical Trial N/A